Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
J Clin Oncol
; 41(32): 4976-4981, 2023 Nov 10.
Article
in En
| MEDLINE
| ID: mdl-37748109
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Clinical_trials
Limits:
Female
/
Humans
Language:
En
Journal:
J Clin Oncol
Year:
2023
Document type:
Article
Affiliation country:
Italy